25 XP   0   0   10

Bukwang Pharm
Buy, Hold or Sell?

Let's analyse Bukwang together

PenkeI guess you are interested in Bukwang Pharm. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Bukwang Pharm. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Bukwang Pharm

I send you an email if I find something interesting about Bukwang Pharm.

Quick analysis of Bukwang (30 sec.)










What can you expect buying and holding a share of Bukwang? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
66.7%

What is your share worth?

Current worth
₩3,422.19
Expected worth in 1 year
₩2,873.17
How sure are you?
66.7%

+ What do you gain per year?

Total Gains per Share
₩-549.02
Return On Investment
-9.2%

For what price can you sell your share?

Current Price per Share
₩5,950.00
Expected price per share
₩5,460 - ₩8,240
How sure are you?
50%

1. Valuation of Bukwang (5 min.)




Live pricePrice per Share (EOD)

₩5,950.00

Intrinsic Value Per Share

₩12,261.43 - ₩14,720.46

Total Value Per Share

₩15,683.61 - ₩18,142.64

2. Growth of Bukwang (5 min.)




Is Bukwang growing?

Current yearPrevious yearGrowGrow %
How rich?$163.9m$189.4m-$11.1m-6.2%

How much money is Bukwang making?

Current yearPrevious yearGrowGrow %
Making money-$5.4m-$433k-$5m-92.1%
Net Profit Margin-33.7%-1.7%--

How much money comes from the company's main activities?

3. Financial Health of Bukwang (5 min.)




What can you expect buying and holding a share of Bukwang? (5 min.)

Welcome investor! Bukwang's management wants to use your money to grow the business. In return you get a share of Bukwang.

What can you expect buying and holding a share of Bukwang?

First you should know what it really means to hold a share of Bukwang. And how you can make/lose money.

Speculation

The Price per Share of Bukwang is ₩5,950. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Bukwang.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Bukwang, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩3,422.19. Based on the TTM, the Book Value Change Per Share is ₩-137.25 per quarter. Based on the YOY, the Book Value Change Per Share is ₩-30.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Bukwang.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.110.0%-0.080.0%-0.020.0%-0.030.0%0.040.0%
Usd Book Value Change Per Share-0.160.0%-0.100.0%-0.020.0%-0.090.0%0.070.0%
Usd Dividend Per Share0.000.0%0.000.0%0.020.0%0.040.0%0.080.0%
Usd Total Gains Per Share-0.160.0%-0.100.0%0.000.0%-0.050.0%0.150.0%
Usd Price Per Share4.27-4.81-6.55-11.10-14.26-
Price to Earnings Ratio-9.67-52.46--165.29--87.42-18.72-
Price-to-Total Gains Ratio-26.56-1,122.68--45.25-283.07-197.11-
Price to Book Ratio1.78-1.84-2.37-3.82-5.59-
Price-to-Total Gains Ratio-26.56-1,122.68--45.25-283.07-197.11-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.165
Number of shares240
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.04
Usd Book Value Change Per Share-0.10-0.09
Usd Total Gains Per Share-0.10-0.05
Gains per Quarter (240 shares)-23.06-12.88
Gains per Year (240 shares)-92.23-51.51
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-92-10236-88-62
20-184-19473-176-114
30-277-286109-264-166
40-369-378146-352-218
50-461-470182-440-270
60-553-562219-528-322
70-646-654255-616-374
80-738-746292-704-426
90-830-838328-792-478
100-922-930364-879-530

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%3.09.00.025.0%6.014.00.030.0%19.016.01.052.8%19.016.01.052.8%
Book Value Change Per Share1.03.00.025.0%5.07.00.041.7%7.013.00.035.0%16.020.00.044.4%16.020.00.044.4%
Dividend per Share0.00.04.00.0%5.00.07.041.7%11.00.09.055.0%24.00.012.066.7%24.00.012.066.7%
Total Gains per Share1.03.00.025.0%6.06.00.050.0%10.010.00.050.0%24.012.00.066.7%24.012.00.066.7%

Fundamentals of Bukwang

About Bukwang Pharm

Bukwang Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products in South Korea and internationally. It offers its products in oral solid dosage forms, injections, oral solutions, external solutions, and ointments. The company also provides ethical drugs, including drugs for treating diabetic peripheral neuropathy, hypothyroidism, toxic liver disease, chronic hepatitis, liver cirrhosis, and iron-deficiency anemia; over-the-counter drugs, such as fever and pain relief medication, gastrointestinal medication, cold medication, laxatives for constipation, collagen supplements, multivitamin supplements, mouthwash, topical gels, oral health supplements, and omega-3 supplements; and personal products comprising toothpastes, toothbrushes, and other oral care products; nutraceuticals; health functional foods; and quasi drugs. In addition, it offers products for various threptic areas, including endocrinology, gastroenterology, cardiology, oncology, central nervous system, iron supplements, neuropsychiatry, respiratory/allergy, dermatology, urology, and other treatment areas. Further, the company's development pipeline comprises Lurasidone for the treatment of schizophrenia and bipolar depression; JM-010, for treating dyskinesia in parkinson's disease; SOL-804, which is used for the treatment of metastatic castration resistant prostate cancer; AhR Inhibitor for solid tumors; PKR Inhibitor for neurodegenerative disorders; and PD Program for parkinson's disease. Bukwang Pharmaceutical Co., Ltd. was founded in 1960 and is headquartered in Seoul, South Korea.

Fundamental data was last updated by Penke on 2024-04-14 20:27:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Bukwang Pharm.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Bukwang earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Bukwang to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -43.2% means that ₩-0.43 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Bukwang Pharm:

  • The MRQ is -43.2%. The company is making a huge loss. -2
  • The TTM is -33.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-43.2%TTM-33.7%-9.5%
TTM-33.7%YOY-1.7%-32.0%
TTM-33.7%5Y-9.2%-24.5%
5Y-9.2%10Y4.5%-13.7%
1.1.2. Return on Assets

Shows how efficient Bukwang is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Bukwang to the Drug Manufacturers - Specialty & Generic industry mean.
  • -2.5% Return on Assets means that Bukwang generated ₩-0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Bukwang Pharm:

  • The MRQ is -2.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -1.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.5%TTM-1.9%-0.6%
TTM-1.9%YOY-0.2%-1.8%
TTM-1.9%5Y-0.6%-1.3%
5Y-0.6%10Y1.0%-1.7%
1.1.3. Return on Equity

Shows how efficient Bukwang is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Bukwang to the Drug Manufacturers - Specialty & Generic industry mean.
  • -4.8% Return on Equity means Bukwang generated ₩-0.05 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Bukwang Pharm:

  • The MRQ is -4.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -3.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-4.8%TTM-3.3%-1.5%
TTM-3.3%YOY-0.2%-3.0%
TTM-3.3%5Y-1.0%-2.3%
5Y-1.0%10Y1.1%-2.1%

1.2. Operating Efficiency of Bukwang Pharm.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Bukwang is operating .

  • Measures how much profit Bukwang makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Bukwang to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Bukwang Pharm:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.5%+0.5%
TTM-0.5%YOY-2.3%+1.8%
TTM-0.5%5Y0.7%-1.2%
5Y0.7%10Y2.5%-1.8%
1.2.2. Operating Ratio

Measures how efficient Bukwang is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 2.37 means that the operating costs are ₩2.37 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Bukwang Pharm:

  • The MRQ is 2.367. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.892. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.367TTM1.892+0.475
TTM1.892YOY1.470+0.422
TTM1.8925Y1.568+0.324
5Y1.56810Y1.283+0.285

1.3. Liquidity of Bukwang Pharm.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Bukwang is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.61 means the company has ₩2.61 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Bukwang Pharm:

  • The MRQ is 2.606. The company is able to pay all its short-term debts. +1
  • The TTM is 5.651. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.606TTM5.651-3.045
TTM5.651YOY5.248+0.402
TTM5.6515Y4.963+0.688
5Y4.96310Y4.399+0.564
1.3.2. Quick Ratio

Measures if Bukwang is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Bukwang to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.37 means the company can pay off ₩0.37 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Bukwang Pharm:

  • The MRQ is 0.366. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 1.931. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ0.366TTM1.931-1.565
TTM1.931YOY2.097-0.165
TTM1.9315Y2.026-0.094
5Y2.02610Y2.240-0.214

1.4. Solvency of Bukwang Pharm.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Bukwang assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Bukwang to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.45 means that Bukwang assets are financed with 45.4% credit (debt) and the remaining percentage (100% - 45.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Bukwang Pharm:

  • The MRQ is 0.454. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.359. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.454TTM0.359+0.095
TTM0.359YOY0.313+0.046
TTM0.3595Y0.292+0.067
5Y0.29210Y0.219+0.074
1.4.2. Debt to Equity Ratio

Measures if Bukwang is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Bukwang to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 86.1% means that company has ₩0.86 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Bukwang Pharm:

  • The MRQ is 0.861. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.593. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.861TTM0.593+0.268
TTM0.593YOY0.473+0.120
TTM0.5935Y0.441+0.152
5Y0.44110Y0.310+0.131

2. Market Valuation of Bukwang Pharm

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Bukwang generates.

  • Above 15 is considered overpriced but always compare Bukwang to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -9.67 means the investor is paying ₩-9.67 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Bukwang Pharm:

  • The EOD is -9.431. Based on the earnings, the company is expensive. -2
  • The MRQ is -9.669. Based on the earnings, the company is expensive. -2
  • The TTM is 52.457. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-9.431MRQ-9.669+0.238
MRQ-9.669TTM52.457-62.126
TTM52.457YOY-165.286+217.743
TTM52.4575Y-87.417+139.874
5Y-87.41710Y18.723-106.140
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Bukwang Pharm:

  • The EOD is 5.964. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 6.115. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is -710.854. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD5.964MRQ6.115-0.150
MRQ6.115TTM-710.854+716.969
TTM-710.854YOY-3.293-707.561
TTM-710.8545Y-91.664-619.189
5Y-91.66410Y-61.568-30.096
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Bukwang is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 1.78 means the investor is paying ₩1.78 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Bukwang Pharm:

  • The EOD is 1.739. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.782. Based on the equity, the company is underpriced. +1
  • The TTM is 1.843. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.739MRQ1.782-0.044
MRQ1.782TTM1.843-0.060
TTM1.843YOY2.367-0.524
TTM1.8435Y3.818-1.975
5Y3.81810Y5.589-1.770
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Bukwang Pharm compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---229.626-137.254-40%-29.996-87%-130.873-43%95.061-342%
Book Value Per Share--3422.1853720.328-8%3952.562-13%4142.783-17%3865.166-11%
Current Ratio--2.6065.651-54%5.248-50%4.963-47%4.399-41%
Debt To Asset Ratio--0.4540.359+26%0.313+45%0.292+55%0.219+108%
Debt To Equity Ratio--0.8610.593+45%0.473+82%0.441+95%0.310+178%
Dividend Per Share----0%25.000-100%54.225-100%114.423-100%
Eps---157.723-114.417-27%-29.727-81%-40.172-75%58.238-371%
Free Cash Flow Per Share--249.397-44.542+118%41.894+495%-3.634+101%15.259+1534%
Free Cash Flow To Equity Per Share--249.397-48.154+119%63.449+293%-41.488+117%-0.120+100%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.972+3%
Intrinsic Value_10Y_max--14720.456--------
Intrinsic Value_10Y_min--12261.425--------
Intrinsic Value_1Y_max--318.122--------
Intrinsic Value_1Y_min--311.793--------
Intrinsic Value_3Y_max--1837.574--------
Intrinsic Value_3Y_min--1736.499--------
Intrinsic Value_5Y_max--4420.077--------
Intrinsic Value_5Y_min--4026.710--------
Market Cap407305488800.000-3%417573694400.000470454953240.000-11%640393755920.000-35%1085989416714.322-62%1394359639231.558-70%
Net Profit Margin---0.432-0.337-22%-0.017-96%-0.092-79%0.045-1060%
Operating Margin----0.0050%-0.0230%0.007-100%0.025-100%
Operating Ratio--2.3671.892+25%1.470+61%1.568+51%1.283+85%
Pb Ratio1.739-3%1.7821.843-3%2.367-25%3.818-53%5.589-68%
Pe Ratio-9.431+2%-9.66952.457-118%-165.286+1609%-87.417+804%18.723-152%
Price Per Share5950.000-3%6100.0006872.500-11%9355.000-35%15863.000-62%20368.334-70%
Price To Free Cash Flow Ratio5.964-3%6.115-710.854+11725%-3.293+154%-91.664+1599%-61.568+1107%
Price To Total Gains Ratio-25.912+2%-26.5651122.682-102%-45.250+70%283.072-109%197.108-113%
Quick Ratio--0.3661.931-81%2.097-83%2.026-82%2.240-84%
Return On Assets---0.025-0.019-23%-0.002-94%-0.006-75%0.010-340%
Return On Equity---0.048-0.033-31%-0.002-95%-0.010-79%0.011-532%
Total Gains Per Share---229.626-137.254-40%-4.996-98%-76.648-67%209.484-210%
Usd Book Value--163985270.568178271756.453-8%189400037.883-13%198524349.144-17%185217302.109-11%
Usd Book Value Change Per Share---0.161-0.096-40%-0.021-87%-0.092-43%0.067-342%
Usd Book Value Per Share--2.3962.604-8%2.767-13%2.900-17%2.706-11%
Usd Dividend Per Share----0%0.017-100%0.038-100%0.080-100%
Usd Eps---0.110-0.080-27%-0.021-81%-0.028-75%0.041-371%
Usd Free Cash Flow--11950696.758-2134385.316+118%2007467.004+495%-174143.353+101%670244.471+1683%
Usd Free Cash Flow Per Share--0.175-0.031+118%0.029+495%-0.003+101%0.011+1534%
Usd Free Cash Flow To Equity Per Share--0.175-0.034+119%0.044+293%-0.029+117%0.000+100%
Usd Market Cap285113842.160-3%292301586.080329318467.268-11%448275629.144-35%760192591.700-62%976051747.462-70%
Usd Price Per Share4.165-3%4.2704.811-11%6.549-35%11.104-62%14.258-70%
Usd Profit---7557801.524-5482690.605-27%-433099.352-94%-1726777.763-77%2900781.457-361%
Usd Revenue--17514644.12622037442.121-21%33409138.858-48%29301376.902-40%28445255.506-38%
Usd Total Gains Per Share---0.161-0.096-40%-0.003-98%-0.054-67%0.147-210%
 EOD+4 -4MRQTTM+8 -24YOY+8 -265Y+7 -2810Y+9 -27

3.2. Fundamental Score

Let's check the fundamental score of Bukwang Pharm based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-9.431
Price to Book Ratio (EOD)Between0-11.739
Net Profit Margin (MRQ)Greater than0-0.432
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.366
Current Ratio (MRQ)Greater than12.606
Debt to Asset Ratio (MRQ)Less than10.454
Debt to Equity Ratio (MRQ)Less than10.861
Return on Equity (MRQ)Greater than0.15-0.048
Return on Assets (MRQ)Greater than0.05-0.025
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Bukwang Pharm based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5036.052
Ma 20Greater thanMa 506,493.500
Ma 50Greater thanMa 1006,528.400
Ma 100Greater thanMa 2006,495.700
OpenGreater thanClose6,000.000
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in KRW. All numbers in thousands.

Summary
Total Assets429,017,049
Total Liabilities194,752,377
Total Stockholder Equity226,311,356
 As reported
Total Liabilities 194,752,377
Total Stockholder Equity+ 226,311,356
Total Assets = 429,017,049

Assets

Total Assets429,017,049
Total Current Assets254,178,523
Long-term Assets174,838,527
Total Current Assets
Cash And Cash Equivalents 151,227,173
Net Receivables 35,729,277
Inventory 56,831,838
Other Current Assets 6,597,153
Total Current Assets  (as reported)254,178,523
Total Current Assets  (calculated)250,385,441
+/- 3,793,082
Long-term Assets
Property Plant Equipment 122,788,510
Goodwill 878,733
Intangible Assets 9,177,450
Long-term Assets  (as reported)174,838,527
Long-term Assets  (calculated)132,844,693
+/- 41,993,834

Liabilities & Shareholders' Equity

Total Current Liabilities97,544,075
Long-term Liabilities97,208,302
Total Stockholder Equity226,311,356
Total Current Liabilities
Accounts payable 2,368,355
Other Current Liabilities 18,463,954
Total Current Liabilities  (as reported)97,544,075
Total Current Liabilities  (calculated)20,832,309
+/- 76,711,765
Long-term Liabilities
Long term Debt 78,525,127
Capital Lease Obligations Min Short Term Debt861,773
Long-term Liabilities Other 1
Long-term Liabilities  (as reported)97,208,302
Long-term Liabilities  (calculated)79,386,900
+/- 17,821,402
Total Stockholder Equity
Retained Earnings 225,783,290
Total Stockholder Equity (as reported)226,311,356
Total Stockholder Equity (calculated)225,783,290
+/- 528,066
Other
Capital Stock36,401,993
Common Stock Shares Outstanding 68,455
Net Invested Capital 304,836,483
Net Working Capital 156,634,448
Property Plant and Equipment Gross 194,538,426



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-31
> Total Assets 
241,962,038
232,078,753
243,583,108
253,660,191
266,682,046
247,159,483
243,471,777
237,634,086
225,957,690
227,658,632
237,532,615
236,229,626
233,895,003
287,887,843
530,991,560
493,615,375
481,066,798
401,981,384
378,935,484
388,534,557
419,935,160
425,335,989
405,225,146
400,968,742
391,267,146
383,906,123
366,002,120
397,416,583
392,238,721
385,765,741
397,795,183
400,929,189
385,636,668
386,874,814
394,279,583
429,017,049
429,017,049394,279,583386,874,814385,636,668400,929,189397,795,183385,765,741392,238,721397,416,583366,002,120383,906,123391,267,146400,968,742405,225,146425,335,989419,935,160388,534,557378,935,484401,981,384481,066,798493,615,375530,991,560287,887,843233,895,003236,229,626237,532,615227,658,632225,957,690237,634,086243,471,777247,159,483266,682,046253,660,191243,583,108232,078,753241,962,038
   > Total Current Assets 
0
0
0
0
0
0
0
134,014,854
124,818,186
121,741,850
123,022,348
124,331,106
118,549,067
175,022,427
236,982,206
221,637,864
239,659,039
194,253,604
185,499,277
186,397,967
238,053,674
252,592,472
246,164,565
248,209,345
245,116,749
236,687,128
218,923,205
220,095,332
216,478,859
212,218,807
224,653,243
218,741,259
206,785,597
206,002,085
214,272,944
254,178,523
254,178,523214,272,944206,002,085206,785,597218,741,259224,653,243212,218,807216,478,859220,095,332218,923,205236,687,128245,116,749248,209,345246,164,565252,592,472238,053,674186,397,967185,499,277194,253,604239,659,039221,637,864236,982,206175,022,427118,549,067124,331,106123,022,348121,741,850124,818,186134,014,8540000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
41,073,231
33,278,088
27,856,563
27,472,554
24,158,380
15,978,967
67,557,105
97,290,165
100,399,748
113,006,175
62,481,108
51,789,631
37,584,814
73,523,446
80,064,836
81,991,653
79,290,780
92,196,915
82,438,427
78,132,817
82,777,135
89,761,720
85,716,608
74,757,617
85,516,748
69,795,775
68,299,761
81,308,942
151,227,173
151,227,17381,308,94268,299,76169,795,77585,516,74874,757,61785,716,60889,761,72082,777,13578,132,81782,438,42792,196,91579,290,78081,991,65380,064,83673,523,44637,584,81451,789,63162,481,108113,006,175100,399,74897,290,16567,557,10515,978,96724,158,38027,472,55427,856,56333,278,08841,073,2310000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
162,966
0
0
0
0
0
0
0
0
0
0
0
8,404,901
7,023,000
10,300,000
0
0
1,700,000
1,500,000
1,000,000
2,000,000
25,000,001
0
0
0
5,000,000
0
05,000,00000025,000,0012,000,0001,000,0001,500,0001,700,0000010,300,0007,023,0008,404,90100000000000162,966000000000
       Net Receivables 
33,875,882
35,133,969
40,574,939
45,305,619
43,891,781
46,158,011
45,320,012
50,189,375
47,364,625
50,684,948
55,380,869
60,181,135
59,755,559
65,516,259
100,196,631
86,557,275
84,639,541
88,552,664
88,350,679
103,029,866
109,918,566
107,001,169
100,076,744
103,984,818
95,121,895
97,672,511
87,380,988
92,841,562
79,969,435
76,013,113
79,297,164
87,950,195
85,722,748
84,644,606
58,296,353
35,729,277
35,729,27758,296,35384,644,60685,722,74887,950,19579,297,16476,013,11379,969,43592,841,56287,380,98897,672,51195,121,895103,984,818100,076,744107,001,169109,918,566103,029,86688,350,67988,552,66484,639,54186,557,275100,196,63165,516,25959,755,55960,181,13555,380,86950,684,94847,364,62550,189,37545,320,01246,158,01143,891,78145,305,61940,574,93935,133,96933,875,882
       Other Current Assets 
447,381
1,014,870
502,056
632,956
2,863,198
5,186,342
4,158,601
3,400,663
2,629,941
2,124,987
631,239
378,530
278,427
509,978
354,741
250,375
-1
-1
0
1,433,722
2,087,760
1,573,529
1,786,730
3,043,045
3,114,224
3,173,005
3,083,151
3,476,453
4,198,752
4,065,088
4,484,169
3,146,884
-1
6,307,541
3,724,492
6,597,153
6,597,1533,724,4926,307,541-13,146,8844,484,1694,065,0884,198,7523,476,4533,083,1513,173,0053,114,2243,043,0451,786,7301,573,5292,087,7601,433,7220-1-1250,375354,741509,978278,427378,530631,2392,124,9872,629,9413,400,6634,158,6015,186,3422,863,198632,956502,0561,014,870447,381
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
241,407,759
207,727,780
193,436,207
202,136,590
181,881,485
162,741,418
159,060,581
152,759,397
146,150,398
147,218,995
147,078,916
177,321,251
175,759,863
173,546,934
173,141,940
182,187,930
178,851,071
180,872,729
180,006,639
174,838,527
174,838,527180,006,639180,872,729178,851,071182,187,930173,141,940173,546,934175,759,863177,321,251147,078,916147,218,995146,150,398152,759,397159,060,581162,741,418181,881,485202,136,590193,436,207207,727,780241,407,7590000000000000000
       Property Plant Equipment 
62,304,462
62,590,894
63,087,555
61,755,250
60,913,572
61,372,048
60,694,778
60,948,802
60,317,577
59,757,512
60,356,454
60,233,784
59,932,545
58,859,870
120,594,662
128,545,118
129,297,238
129,383,497
127,991,314
128,809,267
127,870,571
109,362,776
108,323,131
106,298,457
105,172,776
104,523,279
103,532,103
124,531,104
123,589,008
122,863,760
122,659,516
123,960,350
123,676,629
123,778,229
123,722,807
122,788,510
122,788,510123,722,807123,778,229123,676,629123,960,350122,659,516122,863,760123,589,008124,531,104103,532,103104,523,279105,172,776106,298,457108,323,131109,362,776127,870,571128,809,267127,991,314129,383,497129,297,238128,545,118120,594,66258,859,87059,932,54560,233,78460,356,45459,757,51260,317,57760,948,80260,694,77861,372,04860,913,57261,755,25063,087,55562,590,89462,304,462
       Goodwill 
0
0
0
788,170
788,170
0
758,219
782,653
735,693
0
832,742
788,914
807,848
0
796,803
786,547
0
0
0
796,772
0
0
0
827,050
0
0
0
828,704
0
0
0
834,505
1,884,021
1,629,977
1,629,142
878,733
878,7331,629,1421,629,9771,884,021834,505000828,704000827,050000796,772000786,547796,8030807,848788,914832,7420735,693782,653758,2190788,170788,170000
       Long Term Investments 
0
0
0
0
0
0
0
28,642,223
26,885,091
30,151,962
38,130,023
36,022,545
38,959,649
38,026,285
161,818,667
114,330,601
82,961,781
47,412,375
43,483,658
52,999,638
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000052,999,63843,483,65847,412,37582,961,781114,330,601161,818,66738,026,28538,959,64936,022,54538,130,02330,151,96226,885,09128,642,2230000000
       Intangible Assets 
5,678,278
11,409,420
5,734,803
5,571,830
7,754,671
12,522,620
7,606,577
7,731,541
7,849,726
13,731,505
9,990,524
9,776,148
9,871,190
12,995,907
8,663,201
8,182,833
8,980,259
10,455,123
10,448,605
9,584,714
10,531,602
10,570,166
10,631,375
6,171,958
7,109,472
7,000,954
7,088,758
6,151,418
7,004,157
6,987,893
7,171,561
6,156,588
6,318,609
7,958,646
7,947,348
9,177,450
9,177,4507,947,3487,958,6466,318,6096,156,5887,171,5616,987,8937,004,1576,151,4187,088,7587,000,9547,109,4726,171,95810,631,37510,570,16610,531,6029,584,71410,448,60510,455,1238,980,2598,182,8338,663,20112,995,9079,871,1909,776,1489,990,52413,731,5057,849,7267,731,5417,606,57712,522,6207,754,6715,571,8305,734,80311,409,4205,678,278
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,216,204
1,445,717
1,404,650
252,554
0
367,228
0
1,512,752
0
0
1,683,954
2,008,340
0
0
2,081,488
2,532,948
0
2,870,373
2,811,098
0
02,811,0982,870,37302,532,9482,081,488002,008,3401,683,954001,512,7520367,2280252,5541,404,6501,445,7171,216,2040000000000000000
> Total Liabilities 
40,689,617
26,116,920
27,523,684
28,506,806
51,719,309
27,612,963
25,256,792
23,000,151
24,323,485
23,494,465
24,314,200
24,926,592
28,000,934
39,832,344
91,171,681
80,172,893
76,157,774
76,951,157
57,046,866
62,048,556
133,785,350
138,221,070
118,280,878
129,777,605
130,683,768
124,030,237
105,093,693
117,355,700
122,255,148
115,390,589
127,715,432
129,081,732
118,465,628
119,598,428
144,295,930
194,752,377
194,752,377144,295,930119,598,428118,465,628129,081,732127,715,432115,390,589122,255,148117,355,700105,093,693124,030,237130,683,768129,777,605118,280,878138,221,070133,785,35062,048,55657,046,86676,951,15776,157,77480,172,89391,171,68139,832,34428,000,93424,926,59224,314,20023,494,46524,323,48523,000,15125,256,79227,612,96351,719,30928,506,80627,523,68426,116,92040,689,617
   > Total Current Liabilities 
29,359,062
14,507,437
15,483,619
19,637,042
42,467,452
17,755,587
14,729,897
16,812,983
17,056,727
15,770,027
14,143,795
19,247,217
20,117,042
31,284,817
64,730,514
38,247,166
40,442,343
47,944,303
27,293,135
35,883,741
112,160,141
116,235,270
56,466,781
61,204,348
61,743,868
53,870,361
32,828,861
36,994,751
41,629,757
35,019,694
46,522,020
44,603,056
33,123,718
33,570,438
28,130,410
97,544,075
97,544,07528,130,41033,570,43833,123,71844,603,05646,522,02035,019,69441,629,75736,994,75132,828,86153,870,36161,743,86861,204,34856,466,781116,235,270112,160,14135,883,74127,293,13547,944,30340,442,34338,247,16664,730,51431,284,81720,117,04219,247,21714,143,79515,770,02717,056,72716,812,98314,729,89717,755,58742,467,45219,637,04215,483,61914,507,43729,359,062
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,000,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000013,000,00000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,000,000
0
0
75,000,000
75,000,000
20,000,000
20,000,000
20,000,000
20,000,000
0
0
0
0
10,000,000
0
0
0
0
0
0000010,000,000000020,000,00020,000,00020,000,00020,000,00075,000,00075,000,0000013,000,00000000000000000000
       Accounts payable 
3,340,966
3,028,118
3,070,534
3,413,724
5,538,759
4,475,224
3,603,970
3,278,507
3,819,908
3,601,184
3,577,784
4,682,190
5,220,292
5,771,115
5,602,632
4,339,724
6,468,459
7,644,630
6,638,068
9,890,334
12,278,411
14,599,861
7,408,343
10,156,683
8,270,063
11,275,544
9,133,992
7,420,605
8,586,705
10,898,496
10,866,301
16,529,807
10,915,082
10,424,325
6,873,980
2,368,355
2,368,3556,873,98010,424,32510,915,08216,529,80710,866,30110,898,4968,586,7057,420,6059,133,99211,275,5448,270,06310,156,6837,408,34314,599,86112,278,4119,890,3346,638,0687,644,6306,468,4594,339,7245,602,6325,771,1155,220,2924,682,1903,577,7843,601,1843,819,9083,278,5073,603,9704,475,2245,538,7593,413,7243,070,5343,028,1183,340,966
       Other Current Liabilities 
26,018,096
11,479,319
12,413,085
16,223,318
36,928,693
13,280,363
11,125,927
13,534,476
13,236,819
12,168,843
10,566,011
14,565,027
14,896,750
25,513,702
59,127,882
32,439,037
1,629,857
1,995,288
3,224,104
23,811,471
24,447,432
26,197,793
28,612,554
28,584,380
33,065,821
22,151,297
12,839,214
27,354,159
14,861,450
23,912,593
25,447,114
9,525,905
876,485
22,843,582
11,532,560
18,463,954
18,463,95411,532,56022,843,582876,4859,525,90525,447,11423,912,59314,861,45027,354,15912,839,21422,151,29733,065,82128,584,38028,612,55426,197,79324,447,43223,811,4713,224,1041,995,2881,629,85732,439,03759,127,88225,513,70214,896,75014,565,02710,566,01112,168,84313,236,81913,534,47611,125,92713,280,36336,928,69316,223,31812,413,08511,479,31926,018,096
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
35,715,431
29,006,854
29,753,731
26,164,815
21,625,209
21,985,800
61,814,097
68,573,257
68,939,899
70,159,876
72,264,832
80,360,949
80,625,391
80,370,895
81,193,412
84,478,677
85,341,910
86,027,991
116,165,520
97,208,302
97,208,302116,165,52086,027,99185,341,91084,478,67781,193,41280,370,89580,625,39180,360,94972,264,83270,159,87668,939,89968,573,25761,814,09721,985,80021,625,20926,164,81529,753,73129,006,85435,715,4310000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
27,631
-12,981,110
35,043
2,077,948
1,980,749
1,884,402
1,820,223
1,546,916
1,537,127
1,750,084
1,656,980
1,558,367
1,467,013
1,256,388
1,159,607
930,789
988,528
902,693
800,292
861,773
861,773800,292902,693988,528930,7891,159,6071,256,3881,467,0131,558,3671,656,9801,750,0841,537,1271,546,9161,820,2231,884,4021,980,7492,077,94835,043-12,981,11027,6310000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,974,294
5,442,687
5,563,186
2,034,883
0
2,441,458
0
4,622,141
0
0
5,082,965
1
0
0
0
7,578,428
0
8,440,446
7,874,830
1
17,874,8308,440,44607,578,42800015,082,965004,622,14102,441,45802,034,8835,563,1865,442,6874,974,2940000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
4,237,783
4,059,898
0
3,704,130
3,526,246
3,348,362
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000003,348,3623,526,2463,704,13004,059,8984,237,7830000000
> Total Stockholder Equity
201,272,421
205,961,833
216,059,424
225,153,386
214,962,736
219,546,520
218,214,985
214,633,934
201,634,205
204,164,167
213,218,416
211,303,034
205,894,070
248,055,500
439,785,060
413,412,238
404,883,237
325,010,209
321,700,955
326,246,221
285,896,110
286,880,434
275,420,877
258,499,091
248,573,418
248,092,587
249,357,898
269,607,668
260,188,085
260,927,554
261,415,945
263,217,374
259,007,079
259,753,534
243,365,451
226,311,356
226,311,356243,365,451259,753,534259,007,079263,217,374261,415,945260,927,554260,188,085269,607,668249,357,898248,092,587248,573,418258,499,091275,420,877286,880,434285,896,110326,246,221321,700,955325,010,209404,883,237413,412,238439,785,060248,055,500205,894,070211,303,034213,218,416204,164,167201,634,205214,633,934218,214,985219,546,520214,962,736225,153,386216,059,424205,961,833201,272,421
   Common Stock
17,028,515
17,028,515
17,028,515
17,044,765
18,674,261
18,674,261
18,674,260
18,693,761
22,282,242
22,282,242
22,282,242
22,282,242
24,435,142
24,435,142
24,435,142
24,435,142
31,765,684
31,765,684
31,765,684
31,765,684
33,289,458
33,289,458
33,289,458
33,289,458
36,401,993
36,401,993
36,401,993
36,401,993
36,401,993
36,401,993
36,401,993
0
0
36,401,993
0
0
0036,401,9930036,401,99336,401,99336,401,99336,401,99336,401,99336,401,99336,401,99333,289,45833,289,45833,289,45833,289,45831,765,68431,765,68431,765,68431,765,68424,435,14224,435,14224,435,14224,435,14222,282,24222,282,24222,282,24222,282,24218,693,76118,674,26018,674,26118,674,26117,044,76517,028,51517,028,51517,028,515
   Retained Earnings 
533,605
203,297,026
0
0
291,057
212,819,186
0
208,942,981
193,117,385
194,917,563
198,095,931
198,720,312
194,106,445
196,352,777
340,043,622
334,964,843
320,522,772
308,062,084
291,544,423
310,441,260
270,716,377
273,017,252
266,947,546
273,253,087
260,582,852
260,262,062
260,805,572
264,703,388
255,616,406
255,070,146
254,251,978
258,584,904
253,102,797
254,034,837
237,850,374
225,783,290
225,783,290237,850,374254,034,837253,102,797258,584,904254,251,978255,070,146255,616,406264,703,388260,805,572260,262,062260,582,852273,253,087266,947,546273,017,252270,716,377310,441,260291,544,423308,062,084320,522,772334,964,843340,043,622196,352,777194,106,445198,720,312198,095,931194,917,563193,117,385208,942,9810212,819,186291,05700203,297,026533,605
   Capital Surplus 000000000000000000000000000000000000
   Treasury Stock00000000000000000000000-29,758,480-29,648,520-29,648,520-29,648,520-29,648,520-29,568,227-29,568,227-29,568,227-29,481,165-29,481,165-29,481,165-29,481,165-29,405,754
   Other Stockholders Equity 
0
0
0
0
0
0
0
-239,889
-922,211
-192,427
6,628,867
3,143,692
305,654
1,645,255
48,227,032
26,939,931
25,638,625
8,244,718
5,692,558
6,995,972
4,968,632
3,652,082
-148,149
-4,779,719
-23,743,450
-4,801,813
-4,232,323
11,930,104
-6,646,143
12,883,232
-4,053,855
0
0
13,301,248
0
0
0013,301,24800-4,053,85512,883,232-6,646,14311,930,104-4,232,323-4,801,813-23,743,450-4,779,719-148,1493,652,0824,968,6326,995,9725,692,5588,244,71825,638,62526,939,93148,227,0321,645,255305,6543,143,6926,628,867-192,427-922,211-239,8890000000



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue125,928,241
Cost of Revenue-78,854,725
Gross Profit47,073,51647,073,516
 
Operating Income (+$)
Gross Profit47,073,516
Operating Expense-163,425,001
Operating Income-37,496,760-116,351,485
 
Operating Expense (+$)
Research Development34,551,208
Selling General Administrative22,105,557
Selling And Marketing Expenses0
Operating Expense163,425,00156,656,764
 
Net Interest Income (+$)
Interest Income3,079,805
Interest Expense-3,807,575
Other Finance Cost-0
Net Interest Income-727,769
 
Pretax Income (+$)
Operating Income-37,496,760
Net Interest Income-727,769
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-39,569,386-37,496,760
EBIT - interestExpense = -3,807,575
-31,329,661
-27,522,086
Interest Expense3,807,575
Earnings Before Interest and Taxes (EBIT)0-35,761,811
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-39,569,386
Tax Provision--5,162,874
Net Income From Continuing Ops-34,406,512-34,406,512
Net Income-31,329,661
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0727,769
 

Technical Analysis of Bukwang
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Bukwang. The general trend of Bukwang is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Bukwang's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Bukwang Pharm.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 6,150 < 6,300 < 8,240.

The bearish price targets are: 5,930 > 5,850 > 5,460.

Tweet this
Bukwang Pharm Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Bukwang Pharm. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Bukwang Pharm Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Bukwang Pharm. The current macd is -176.84829281.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Bukwang price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Bukwang. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Bukwang price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Bukwang Pharm Daily Moving Average Convergence/Divergence (MACD) ChartBukwang Pharm Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Bukwang Pharm. The current adx is 19.53.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Bukwang shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Bukwang Pharm Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Bukwang Pharm. The current sar is 6,651.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Bukwang Pharm Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Bukwang Pharm. The current rsi is 36.05. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Bukwang Pharm Daily Relative Strength Index (RSI) ChartBukwang Pharm Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Bukwang Pharm. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Bukwang price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Bukwang Pharm Daily Stochastic Oscillator ChartBukwang Pharm Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Bukwang Pharm. The current cci is -96.36353257.

Bukwang Pharm Daily Commodity Channel Index (CCI) ChartBukwang Pharm Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Bukwang Pharm. The current cmo is -38.83674908.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Bukwang Pharm Daily Chande Momentum Oscillator (CMO) ChartBukwang Pharm Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Bukwang Pharm. The current willr is -94.23868313.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Bukwang Pharm Daily Williams %R ChartBukwang Pharm Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Bukwang Pharm.

Bukwang Pharm Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Bukwang Pharm. The current atr is 290.72.

Bukwang Pharm Daily Average True Range (ATR) ChartBukwang Pharm Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Bukwang Pharm. The current obv is 37,488,356.

Bukwang Pharm Daily On-Balance Volume (OBV) ChartBukwang Pharm Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Bukwang Pharm. The current mfi is 49.75.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Bukwang Pharm Daily Money Flow Index (MFI) ChartBukwang Pharm Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Bukwang Pharm.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-24CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-27ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-28WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-15BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-23WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-24MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-06MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Bukwang Pharm Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Bukwang Pharm based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5036.052
Ma 20Greater thanMa 506,493.500
Ma 50Greater thanMa 1006,528.400
Ma 100Greater thanMa 2006,495.700
OpenGreater thanClose6,000.000
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Bukwang with someone you think should read this too:
  • Are you bullish or bearish on Bukwang? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Bukwang? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Bukwang Pharm

I send you an email if I find something interesting about Bukwang Pharm.


Comments

How you think about this?

Leave a comment

Stay informed about Bukwang Pharm.

Receive notifications about Bukwang Pharm in your mailbox!